Hormonal
GLP-1 receptor agonists promote significant weight loss in adults with obesity or overweight, with semaglutide 2.4 mg showing superior efficacy compared to placebo and other agents.
For significant weight loss, GLP-1 RAs like semaglutide (Wegovy) or tirzepatide (Zepbound/Mounjaro) are highly effective, producing 15% or more body weight loss in clinical trials. They work by reducing appetite and slowing digestion. While side effects like nausea are common, they often improve over time. These drugs are most effective when combined with lifestyle changes.
Semaglutide led to a 14.9% mean weight loss vs 2.4% with placebo... Tirzepatide resulted in greater weight loss compared to semaglutide at 72 weeks.
Why this rating
Supported by large RCTs (STEP 1, SURMOUNT-1) with clear, statistically significant weight loss data.
Source
Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review
Bisma Fatima Hammad et al. · Frontiers in Clinical Diabetes and Healthcare · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →